Xilio Therapeutics Expands Team with Stock Options Grant
Xilio Therapeutics Expands Team with Stock Options Grant
Xilio Therapeutics, Inc. (Nasdaq: XLO), a cutting-edge biotechnology firm focused on developing tumor-activated immuno-oncology therapies, is making significant strides in its mission to support those living with cancer. In an exciting development, the company has announced the granting of a non-qualified stock option to a new employee, effective from the start of the year.
Stock Options Details
The stock option allows the new employee to purchase up to 60,000 shares of Xilio's common stock. The exercise price is set at $0.955 per share, matching the closing stock price from the previous day, December 31, 2024. This stock option has a ten-year term and is set to vest gradually, with the first 25% becoming available on the employee's one-year anniversary and the subsequent 75% vesting in equal monthly installments over three years.
Plan Compliance
This initiative is in line with Xilio Therapeutics' 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). By integrating this stock option grant into their employment strategy, Xilio ensures they attract and retain top talent essential for advancing their innovative therapies.
About Xilio Therapeutics
Xilio Therapeutics is at the forefront of biotechnology, dedicated to developing groundbreaking treatments that revolutionize cancer therapy. Their approach is centered around tumor-activated immuno-oncology (I-O) therapies, aiming to improve patient outcomes while minimizing the systemic side effects often associated with traditional I-O treatments.
Innovative Research and Development
Through its proprietary platform, Xilio is advancing a promising pipeline of clinical and preclinical I-O products. These innovative therapies include tumor-activated cytokines, antibodies, and immune cell engagers, all designed to enhance the efficacy of cancer treatments by focusing anti-tumor activity directly within the tumor microenvironment.
Engaging the Community
Xilio is committed to involving the medical community and investors in its journey. By supplementing their workforce with skilled professionals, they ensure that continuous research and clinical advancements are achievable. Interested individuals can learn more about their initiatives by visiting Xilio's official website or searching for updates online.
Frequently Asked Questions
What type of stock options did Xilio grant to its new employee?
Xilio granted a non-qualified stock option to purchase 60,000 shares of its common stock.
What is the exercise price for the stock options?
The exercise price is set at $0.955 per share, equivalent to the closing price on December 31, 2024.
How long are the stock options valid?
The stock options have a ten-year term from the date of the grant.
What percentage of the stock options will vest first?
25% of the shares will vest after one year of employment, with the remaining 75% vesting monthly over the following three years.
What is the goal of Xilio Therapeutics?
Xilio Therapeutics aims to improve patient outcomes in cancer treatment while minimizing side effects through advanced, tumor-targeted therapies.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.
